This week, we discuss an interim analysis of the MONALEESA-7 trial of the addition of ribociclib to endocrine therapy in pre- or perimenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer. 

We also talk about a study that examined the relationship between the duration of chemotherapy and body mass index and the development of lymphedema in some patients with breast cancer.

Lastly, we present three recent approvals and regulatory communications from the FDA.

Coverage of stories discussed this week on ascopost.com:

Overall Survival With the Addition of Ribociclib to Endocrine Therapy in Advanced HR-Positive, HER2-Negative Breast Cancer

Neoadjuvant Chemotherapy Duration and Obesity May Be Associated With Increased Risk of Lymphedema in Some Women With Breast Cancer

FDA Approves Rituximab Biosimilar for Non-Hodgkin Lymphoma, CLL, and Autoimmune Conditions

FDA Requests Manufacturer Recall of Some Textured Breast Implants

FDA Approves Pembrolizumab for Some Patients With PD-L1–Positive Esophageal Cancer